semaglutide hemodialysis pharmacokinetics a-b Variability of PK under steadystate conditions (a) and Hemoglobin A1c Reduction With the

Im so nauseous

Monitoring and Follow-Up During Retatrutide Treatment Trial participants undergo structured monitoring of weight, blood glucose, HbA1c, lipids, liver and renal function, blood pressure, and heart rate, typically every four weeks during dose escalation

Planta 211(1):5061

References Huang, T., Zhang, K., Sun, L., Xue, X., Zhang, C., Shu, Z., Mu, N., Gu, J., Zhang, W., Wang, Y., Zhang, Y., & Zhang, W

People with Type 2 diabetes have a higher risk of heart attacks and strokes GLP-1s may help reduce these risks

The positive effects can last several weeks, with ongoing treatments recommended for lasting benefits